Thus, our results demonstrate that the functional properties of the NANOG-TRPV1-pEGFR axis are conserved across NANOGhigh lung and gastric cancer cells, and TRPV1 could be a potential target for controlling NANOGhigh cisplatin-resistant cancer. Here, TRPV1 is linked to gastric cancer.